Skip to main content

Table 1 Clinical characteristics of the patients

From: Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase

 

Sema4A high (≥ 2500 U/ml) (n = 63)

Sema4A low (< 2500 U/ml) (n = 138)

P

Female/male (% female)

51/12 (81.0)

112/26 (81.2)

0.972

Age at onset (mean ± SD, years)

28.8 ± 8.4

34.8 ± 9.7

0.00004*

Disease duration from onset to examination (mean ± SD, years)

6.3 ± 8.5

8.1 ± 6.9

0.125

Sema4A (mean ± SD, U/mL)

26,003.7 ± 108,879.5

439.9 ± 635.2

Positive ratio of OCB (n/N, (%))

29/46 (63.0)

54/104 (51.9)

0.207

Distribution of MRI lesions (n/N, (%))

 - Cerebrum

59/62 (95.2)

129/138 (93.5)

0.643

 - Cerebellum

10/60 (16.7)

25/138 (18.1)

0.806

 - Brain stem

27/62 (43.5)

72/138 (52.2)

0.259

 - Spinal cord

45/61 (73.8)

93/137 (67.9)

0.405

 - Optic nerve

22/61 (36.1)

45/136 (33.1)

0.683

EDSS change before Sema4A analysis (mean ± SD, /year)

0.7 ± 0.5

0.4 ± 0.5

0.01*

ARR before Sema4A analysis (mean ± SD, /year)

1.13 ± 0.94

0.83 ± 0.74

0.04*